1800 244 735

Helpline (02) 9874 9777

No surprises in published results from HART study of Huntexil for Huntington's disease

A new paper in the journal Movement Disorders reports the findings of the HART study of pridopidine, also known as Huntexil – a new drug aimed at improving movements in people with Huntington’s disease. Unfortunately this publication doesn’t change much – a new, larger trial is still needed before we will know whether Huntexil works.

Pridopidine, aka Huntexil

Huntexil is an experimental drug which it’s hoped may be beneficial for improving the movement problems experienced by people with Huntington’s disease. It is thought to act by stabilising the behavior of the brain transmitter dopamine. Also known by its chemical name pridopidine, Huntexil was developed by the Danish company NeuroSearch and acquired by Israeli drug giant Teva in 2012. Announced shortly after Dr Michael Hayden took over as Chief Scientific Officer in 2012, the acquisition of Huntexil represented a new commitment to HD research by Teva.

HART

The HART trial precedes Teva’s involvement, and was one of two large trials conducted by NeuroSearch before they sold the drug. HART involved 227 volunteers with Huntington’s disease and was conducted in the USA between 2008 and 2010. The results of the study are fairly well-known since they’ve been announced at various scientific conferences and in press releases, and we’ve written about them here at HDBuzz, too.

The reason Huntexil has raised its head now is that the findings have just been published in the scientific journal Movement Disorders, after a fairly lengthy three-year delay.

Volunteers were given one of three different doses of Huntexil, or a dummy ‘placebo’ tablet, for three months. The drug was safe and well-tolerated, though one patient on a medium dose experienced seizures.

The results were analysed according to a plan that had been set out in advance. That’s important to avoid the pitfall of ‘fishing’ for positive results and only presenting those that happen to be favourable. According to the pre-specified analysis, Huntexil didn’t improve volunteers' movements at any dose. It came close on a couple of ‘secondary’ measures, but essentially the trial was negative.

The broader context

While it’s good that the data from HART are now published, this new paper doesn’t contain any surprises, and it doesn’t change what needs to happen next for Huntexil to get licensed.

HART is one of two large studies of Huntexil carried out by NeuroSearch. Results of the larger study, MermaiHD, were published in 2011 and again, the drug failed to meet the pre-specified level of success to declare the result positive.

When the pooled results of both trials were presented to the European and American regulators, the EMA and the FDA, NeuroSearch was told that it would need to run a third large trial that met the pre-specified tests for success, in order to get a license for the drug. One question was whether the trials had used high enough doses of Huntexil to get the biggest effect.

Teva has announced its intention to “design and complete new clinical studies of Huntexil”, so we can hopefully look forward to an announcement of such a trial in the near future.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.